Up-regulation of integrin β3 in radioresistant pancreatic cancer impairs adenovirus-mediated gene therapy

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1902-1907

  Egami, Takuya ^a   Ohuchida, Kenoki ^a   Yasui, Takaharu ^a   Mizumoto, Kazuhiro ^b   Onimaru, Manabu ^a   Toma, Hiroki ^a   Sato, Norihiro ^a   Matsumoto, Kunio ^c   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA3 INTEGRIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GENE THERAPY AGENT; PROTEIN NK4; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; CELL LINE, TUMOR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTEGRIN BETA3; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; UP-REGULATION;

EID: 70349585447     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01245.x     Document Type: Article

References (53)

1. Gunzburg WH, Salmons B. Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol Med 2001, 7:30-7.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Eng J Med 1992, 326:455-65.
3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995, 82:111-5.
4. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature Rev 2002, 2:897-909.
5. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002, 2:25-8.
6. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995, 55:1129-38.
7. Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002, 9:668-74. 2nd
8. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006, 13:286-95.
9. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006, 5:787-96.
10. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004, 5:541-9.
11. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol 2006, 133:9-29.
12. Bergelson JM, Cunningham JA, Droguett G. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, NY) 1997, 275:1320-3.
13. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73:309-19.
14. Wang K, Guan T, Cheresh DA, Nemerow GR. Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol 2000, 74:2731-9.
15. Wang K, Huang S, Kapoor-Munshi A, Nemerow G. Adenovirus internalization and infection require dynamin. J Virol 1998, 72:3455-8.
16. Ogura Y, Mizumoto K, Nagai E. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther 2006, 13:520-9.
17. Murakami M, Nagai E, Mizumoto K. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer 2005, 117:160-5.
18. Mulvihill S, Warren R, Venook A. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001, 8:308-15.
19. Sangro B, Mazzolini G, Ruiz J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004, 22:1389-97.
20. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003, 66:1-9.
21. Geoerger B, Grill J, Opolon P. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 2003, 89:577-84.
22. Portella G, Pacelli R, Libertini S. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003, 88:5027-32.
23. Rogulski KR, Freytag SO, Zhang K. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000, 60:1193-6.
24. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994, 54:5775-8.
25. Paciucci R, Vila MR, Adell T. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am J Pathol 1998, 153:201-12.
26. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 2001, 84:864-73.
27. Maehara N, Nagai E, Mizumoto K. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 2002, 19:417-26.
28. Saimura M, Nagai E, Mizumoto K. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther 2002, 9:799-806.
29. Egami T, Ohuchida K, Mizumoto K. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res 2008, 14:1859-67.
30. Zhang L, Mizumoto K, Sato N. Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin. Cancer Lett 1999, 142:129-37.
31. Maemondo M, Narumi K, Saijo Y. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002, 5:177-85.
32. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988, 163:614-7.
33. Korst RJ, Bewig B, Crystal RG. In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum Gene Ther 1995, 6:277-87.
34. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997, 420:1-6.
35. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther 2003, 8:21-8.
36. Ohuchida K, Mizumoto K, Ohhashi S. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 2006, 12:5417-22.
37. Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res 2005, 65:5493-7.
38. Hingorani M, White CL, Merron A. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res 2008, 68:9771-8.
39. Medina-Kauwe LK. Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev 2003, 55:1485-96.
40. Greber UF, Webster P, Weber J, Helenius A. The role of the adenovirus protease on virus entry into cells. EMBO J 1996, 15:1766-77.
41. Chardonnet Y, Dales S. Early events in the interaction of adenoviruses with HeLa cells. II. Comparative observations on the penetration of types 1, 5, 7, and 12. Virology 1970, 40:478-85.
42. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994, 127:257-64.
43. Majhen D, Nemet J, Richardson J. Differential role of alpha (v) beta (3) and alpha (v) beta (5) integrins in internalization and transduction efficacies of wild type and RGD4C fiber-modified adenoviruses. Virus Res 2009, 139:64-73.
44. Lacher MD, Tiirikainen MI, Saunier EF. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006, 66:1648-57.
45. Davison E, Kirby I, Whitehouse J, Hart I, Marshall JF, Santis G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha (v) beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med 2001, 3:550-9.
46. Ambriovic-Ristov A, Gabrilovac J, Cimbora-Zovko T, Osmak M. Increased adenoviral transduction efficacy in human laryngeal carcinoma cells resistant to cisplatin is associated with increased expression of integrin alphavbeta3 and coxsackie adenovirus receptor. Int J Cancer 2004, 110:660-7.
47. Belluci S, Caen J. Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev 2002, 16:193-202.
48. Switala-Jelen K, Dabrowska A, Opolski A. The biological functions of β3 integrins. Folia Biol 2004, 50:143-52.
49. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003, 2:703-16.
50. Yano J, Hirabayashi K, Nakagawa S. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004, 10:7721-6.
51. Nogawa M, Yuasa T, Kimura S. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005, 115:978-85.
52. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-70.
53. Takeshita F, Minakuchi Y, Nagahara S. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005, 102:12177-82.